- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Genmab AS(GMAB)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for GMAB
11/13/2026: GMAB (5-star) is a STRONG-BUY. BUY for 95 days. Simulated Profits (80.12%). Updated daily EoD!
Genmab AS is an international biotechnology company known for developing antibody-based therapeutics through advanced engineering platforms and co-development partnerships. The company's primary business strengths include robust, high-margin royalty streams from blockbusters like DARZALEX and Kesimpta, paired with growing product sales from EPKINLY. Its main growth opportunity lies in expanding its proprietary commercial portfolio and advancing late-stage oncology candidates into earlier treatment lines. However, key risks involve high revenue concentration tied to its main partners, increasing operational expenses, and intense biotechnology competition. Genmab suits growth-oriented healthcare investors who should closely monitor pipeline execution and royalty trends.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Genmab offers strong top-line revenue growth driven by double-digit royalty increases and expanding proprietary drug sales. |
| Momentum investor | Strong fit while signal remains positive | Positive clinical trial readouts and upwardly revised financial guidance can spark sharp near-term upward momentum. |
| Value investor | Mixed fit | While profitable with solid cash flows, its biotech valuation multiples require careful assessment against pipeline execution risks. |
| Dividend investor | Weak fit | Genmab does not pay a regular cash dividend, opting instead to reinvest earnings into clinical development and growth. |
| Low-risk investor | Weak fit | As a biotechnology stock subject to clinical trial outcomes, regulatory milestones, and partner concentration, volatility is inevitable. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | Biotech share prices fluctuate significantly based on regulatory decisions, clinical trial results, and broader market sentiment. |
| Valuation risk | Medium | Investors price in high expectations for pipeline assets, leaving little margin for error if commercial milestones miss targets. |
| Competition risk (biopharmaceutical therapeutic competition) | High | Intense rivalry from alternative oncology modalities like CAR-T cell therapies and rival bispecific antibodies threatens long-term market share. |
| Business quality | Strong | Genmab possesses world-class antibody engineering technology platforms and a proven, high-margin royalty business model. |
| Dividend income | Low / none | The company does not distribute regular dividends to common stockholders. |
| Execution risk | Medium / high | Successfully transitioning from a royalty-dependent model to a self-reliant commercial biopharma enterprise requires flawless operational execution. |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 31.67B USD | Price to earnings Ratio 43.91 | 1Y Target Price 65.1 |
Price to earnings Ratio 43.91 | 1Y Target Price 65.1 | ||
Volume (30-day avg) 5.9M shares | Beta 0.52 | 52 Weeks Range 23.62 - 59.97 | Updated Date 11/15/2026 |
52 Weeks Range 23.62 - 59.97 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.17 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 74.24% | Avg. Invested days 50 | Today’s Advisory Regular Buy |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Royalty Revenue | Royalties earned from partner-commercialized blockbuster medicines like DARZALEX and Kesimpta. | This is Genmab's primary profit engine, providing steady cash flow backed by major global pharma partners. |
| Net Product Sales and Collaborations | Direct commercial sales and co-promotion profits from proprietary drugs like EPKINLY and Tivdak. | Represents Genmab's expanding effort to capture direct product revenues rather than relying solely on partner royalties. |
| Milestones and Reimbursements | Upfront payments, clinical milestone achievements, and research funding from codevelopment partners. | Lump-sum cash inflows that validate pipeline progress and supplement ongoing core operational revenue. |
Earnings Date
Report Date 2026-11-05 | When Before Market | Estimate 0.36 | Actual 0.56 |
Profitability
Profit Margin 16.97% | Operating Margin (TTM) 30.63% |
Management Effectiveness
Return on Assets (TTM) 8.24% | Return on Equity (TTM) 12.07% |
Valuation
Trailing PE 43.91 | Forward PE 22.17 | Enterprise Value 34.76B | Price to Sales(TTM) 7.37 |
Enterprise Value 34.76B | Price to Sales(TTM) 7.37 | ||
Enterprise Value to Revenue 8.09 | Enterprise Value to EBITDA 27.63 | Shares Outstanding 616.59M | Shares Floating 589.06M |
Shares Outstanding 616.59M | Shares Floating 589.06M | ||
Percent Insiders 0.1 | Percent Institutions 20.9 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

